
Novel Targeted Therapy for Pancreatic CancerAward last edited on: 2/18/19
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$299,979Award Phase
1Solicitation Topic Code
-----Principal Investigator
Victoria L HerreraCompany Information
Phase I
Contract Number: 1R43CA221555-01A1Start Date: 4/1/18 Completed: 3/31/19
Phase I year
2018Phase I Amount
$299,979Public Health Relevance Statement:
This research aims to advance the translation to the clinic of a potential first-in-class fully humanized anti- DEspR antibody, ABT-468, as novel cancer therapy with a three-pronged mechanism of action which inhibits key players in metastasis: cancer stem cells (CSC), tumor blood vessel formation, and activated neutrophils which promote tumor cell invasiveness and immune-evasion. We propose to rigorously test ABT-468 in a CSC-derived xenograft tumor model pancreatic peritoneal metastasis, which has no curative- intent therapy. Completion of this SBIR Phase I will attain key milestones towards IND-filing for ABT-468, in order to advance translation to the clinic for PDAC, and in future, therapy for other metastatic cancers.
Project Terms:
Address; Adjuvant Chemotherapy; Adjuvant Therapy; Adverse event; Affinity; angiogenesis; Angiogenesis Inhibition; Anoikis; Antibodies; Apoptosis; Ascites; Avastin; base; Biliary; Binding; Biological; Biological Markers; Blinded; blood vessel development; Cachexia; cancer stem cell; cancer therapy; Carcinoma; Carcinomatosis; Cell surface; Cell Survival; Cells; chemotherapy; Clinic; Clinical; clinical predictors; clinical translation; clinically relevant; Colon; Colon Carcinoma; Combined Modality Therapy; Comorbidity; Complex; Data; Detection; Disseminated Malignant Neoplasm; Dose; Duct (organ) structure; Early treatment; efficacy study; efficacy testing; efficacy trial; Endothelial Cells; Exhibits; exosome; experimental study; Female; Future; gemcitabine; Goals; Hematogenous; Hepatic; Hour; Human; Icterus; IgG4; Immune Evasion; improved; in vivo; Induction of Apoptosis; insight; Ischemia; Lead; Legal patent; Link; live cell imaging; Lymphocyte; Maintenance; male; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Malignant Neoplasms; Measurement; Membrane; Modeling; Molecular; Monoclonal Antibodies; mouse model; murine monoclonal antibody; Mus; Neoplasm Metastasis; Neoplasms in Vascular Tissue; neoplastic cell; neutralizing antibody; Neutropenia; neutrophil; new therapeutic target; Normal tissue morphology; novel; novel therapeutics; Nude Rats; Obstruction; Operative Surgical Procedures; outcome forecast; Pancreas; pancreas xenograft; Pancreatic carcinoma; Patients; Peritoneal; Phase; phase 1 testing; Placebo Control; Placebos; pre-clinical; prevent; Prevention; Primary Neoplasm; Rattus; receptor; Research; Resected; Resistance; response; Role; Safety; self-renewal; Severities; sex; Signal Transduction; Site; Small Business Innovation Research Grant; Solid Neoplasm; standard of care; Statistical Data Interpretation; stem-like cell; Stomach; Surrogate Markers; targeted treatment; Testing; therapeutic evaluation; Toxic effect; Translations; Treatment Failure; treatment response; tumor; Tumor Debulking; tumor growth; tumor xenograft; Tumor-Derived; Vascular Endothelial Growth Factors; Xenograft Model; Xenograft pr
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00